ArticleThe Journal of biological chemistry2014
Role of glucocorticoid-induced leucine zipper (GILZ) in bone acquisition.
Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Effects of Systemic Peroxisome Proliferator-Activated Receptor Gamma Inhibition on Bone and Immune Cells in Aged Female Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Review
- Deletion of PPARγ in Mesenchymal Lineage Cells Protects Against Aging-Induced Cortical Bone Loss in Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- Glucocorticoid-Induced Leucine Zipper: A Promising Marker for Monitoring and Treating Sepsis.Frontiers in immunology · 2020Review
- The shift in the balance between osteoblastogenesis and adipogenesis of mesenchymal stem cells mediated by glucocorticoid receptor.Stem cell research & therapy · 2019Review
- Peroxisome Proliferator-Activated Receptor-γ Knockdown Impairs Bone Morphogenetic Protein-2-Induced Critical-Size Bone Defect Repair.The American journal of pathology · 2019Article
- Glucocorticoid-Induced Leucine Zipper: A Novel Anti-inflammatory Molecule.Frontiers in pharmacology · 2019Review
- Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?Frontiers in immunology · 2019Review
- Long non-coding RNA TCONS_00041960 enhances osteogenesis and inhibits adipogenesis of rat bone marrow mesenchymal stem cell by targeting miR-204-5p and miR-125a-3p.Journal of cellular physiology · 2018Article
- Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation.Frontiers in aging neuroscience · 2018Article
- Glucocorticoid-Induced Leucine Zipper: Fine-Tuning of Dendritic Cells Function.Frontiers in immunology · 2018Review
- Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease.Molecular neurobiology · 2017Review
- Article
- Crosstalk between bone marrow-derived mesenchymal stem cells and regulatory T cells through a glucocorticoid-induced leucine zipper/developmental endothelial locus-1-dependent mechanism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Impact of targeted PPARγ disruption on bone remodeling.Molecular and cellular endocrinology · 2015Article
- GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids.Frontiers in endocrinology · 2015Review
- The CNTN1/Gilz pathway mediates the therapeutic effect of mesenchymal stem cells onCell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Glucocorticoids (GCs) have both anabolic and catabolic effects on bone. However, no GC anabolic effect mediator has been identified to date. Here we show that targeted expression of glucocorticoid-induced leucine zipper (GILZ), a GC anti-inflammatory effect mediator, enhances bone acquisition in mice. Transgenic mice, in which the expression of GILZ is under the control of a 3.6-kb rat type I collagen promoter, exhibited a high bone mass phenotype with significantly increased bone formation rate and osteoblast numbers. The increased osteoblast activity correlates with enhanced osteogenic differentiation and decreased adipogenic differentiation of bone marrow stromal cell cultures in vitro. In line with these changes, the mRNA levels of key osteogenic regulators (Runx2 and Osx) increased, and the level of adipogenic regulator peroxisome proliferator-activated receptor (PPAR) γ2 decreased significantly. We also found that GILZ physically interacts with C/EBPs and disrupts C/EBP-mediated PPARγ gene transcription. In conclusion, our results showed that GILZ is capable of increasing bone acquisition in vivo, and this action is mediated via a mechanism involving the inhibition of PPARγ gene transcription and shifting of bone marrow MSC/progenitor cell lineage commitment in favor of the osteoblast pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.